The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality and survivorship. It also outlines how basic, translational and clinical cancer research and cancer-related population science—largely supported by federal investments in the National Institutes of Health (NIH), the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC)—are improving health and saving lives.

In the SWOG S1827 MAVERICK Phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure-free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, South Korea.

A new approach to modeling vocal fold fatigue could improve detection and monitoring of problems as they arise, particularly among people whose jobs depend on sustained voice use. The research, published in the International Journal of Information and Communication Technology, uses a physics-based framework to track changes over time.

New sexual health data released by the Kirby Institute at UNSW Sydney show a mixed picture for Australia, with rates of syphilis and gonorrhea remaining high after significant increases since 2016—and chlamydia stable but still the most commonly notified sexually transmitted infection (STI). First Nations peoples continue to experience higher rates of all STIs, highlighting the need for sustained investment in culturally safe sexual health services.

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).